Explainable Artificial Intelligence: A Perspective on Drug Discovery
Pharmaceutics · 27.08.2025 · 17 (9) · 1119
DOI: 10.3390/pharmaceutics17091119 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 27.08.2025. Verfasst von Yazdan Ahmad Qadri und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Computer Science and Engineering, Yeungnam University, Gyeongsan-si 38541, Republic of Korea. Die Arbeit wurde bisher 76-mal zitiert (Crossref) und nennt 139 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Norwegian Research Council.
Abstract (Originalsprache)
The convergence of artificial intelligence (AI) and drug discovery is accelerating the pace of therapeutic target identification, refining of drug candidates, and streamlining processes from laboratory research to clinical applications. Despite these promising advances, the inherent opacity of AI-driven models, especially deep-learning (DL) models, poses a significant “black-box" problem, limiting interpretability and acceptance within the pharmaceutical researchers. Explainable artificial intelligence (XAI) has emerged as a crucial solution for enhancing transparency, trust, and reliability by clarifying the decision-making mechanisms that underpin AI predictions. This review systematically investigates the principles and methodologies underpinning XAI, highlighting various XAI tools, models, and frameworks explicitly designed for drug-discovery tasks. XAI applications in healthcare are explored with an in-depth discussion on the potential role in accelerating the drug-discovery processes, such as molecular modeling, therapeutic target identification, Absorption, Distribution, Metabolism, and Excretion (ADME) prediction, clinical trial design, personalized medicine, and molecular property prediction. Furthermore, this article critically examines how XAI approaches effectively address the black-box nature of AI models, bridging the gap between computational predictions and practical pharmaceutical applications. Finally, we discuss the challenges in deploying XAI methodologies, focusing on critical research directions to improve transparency and interpretability in AI-driven drug discovery. This review emphasizes the importance of researchers staying current on evolving XAI technologies to realize their transformative potential in fully improving the efficiency, reliability, and clinical impact of drug-discovery pipelines.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Computer Science and Engineering, Yeungnam University, Gyeongsan-si 38541, Republic of Korea.
- Department of Medical Biotechnology, Yeungnam University, Gyeongsan-si 38541, Republic of Korea.
- Research Institute of Cell Culture, Yeungnam University, Gyeongsan-si 38541, Republic of Korea.
- Department of Health Informatics, College of Applied Medical Sciences, Qassim University, Buraydah 51452, Saudi Arabia.
- Department of Information and Communication Technology, University of Agder, 4879 Grimstad, Norway.
ORCID-Profile: Yazdan Ahmad Qadri, Sibhghatulla Shaikh, Khurshid Ahmad, Inho Choi, Sung Won Kim, Athansios V Vasilakos
Förderung
- Norwegian Research Council
Zitieren
APA
Qadri, Y. A., Shaikh, S., Ahmad, K., Choi, I., Kim, S. W., & Vasilakos, A. V. (2025). Explainable Artificial Intelligence: A Perspective on Drug Discovery. Pharmaceutics, 17(9), 1119. https://doi.org/10.3390/pharmaceutics17091119
Vancouver
Qadri YA, Shaikh S, Ahmad K, Choi I, Kim SW, Vasilakos AV. Explainable Artificial Intelligence: A Perspective on Drug Discovery. Pharmaceutics. 2025;17(9):1119. doi:10.3390/pharmaceutics17091119
BibTeX
@article{Qadri2025,
author = {Qadri, Yazdan Ahmad and Shaikh, Sibhghatulla and Ahmad, Khurshid and Choi, Inho and Kim, Sung Won and Vasilakos, Athansios V},
title = {Explainable Artificial Intelligence: A Perspective on Drug Discovery},
journal = {Pharmaceutics},
year = {2025},
volume = {17},
number = {9},
pages = {1119},
doi = {10.3390/pharmaceutics17091119}
}
EUVIMED